Business Context and Reporting Period
This Form 8-K was filed by Scilex Holding Co (SCLX) on September 22, 2025. The report details corporate governance changes occurring in connection with a previously announced business combination involving Denali Capital Acquisition Corp., Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. (a majority-owned subsidiary of Scilex).
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a new compensatory arrangement:
- Consulting Fee: $50,000 per month.
- Contract Duration: Five years.
- Counterparty: Inform LLC, an entity affiliated with former director Jaisim Shah.
Material Changes
The following material changes to the Board of Directors were effective immediately on September 22, 2025:
- Resignations: Annu Navani and Jaisim Shah resigned as directors. The filing explicitly states neither resigned due to any disagreement with the Company regarding operations, policies, or practices.
- Board Size Reduction: The Board size was decreased from six directors to five directors.
- Appointment: Stephen Ma, the Company's Chief Financial Officer, Senior Vice President, and Secretary, was appointed to fill the vacancy created by the resignations and board size reduction.
Outlook, Risks, and Unusual Items
Management Commentary and Context: The changes are directly tied to the ongoing Business Combination. Stephen Ma's appointment was not the result of any arrangement or understanding with any person, and no family relationships exist between him and other directors or officers.
Related Party Transaction: A consulting agreement was entered into with Inform LLC (affiliated with Jaisim Shah) immediately following his resignation. Certain details of this agreement were redacted from the public filing as confidential, though the core terms (fee and duration) are disclosed.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond the standard execution of the business combination.
Investor Verification Checklist
- Verify the status and expected closing date of the business combination with Denali Capital Acquisition Corp. and Semnur Pharmaceuticals.
- Review the full text of the Consulting Agreement (Exhibit 10.1) to understand the specific scope of services Inform LLC will provide.
- Confirm the composition of the new five-member Board of Directors and the specific roles of the remaining directors.
- Monitor future filings for any additional executive departures or appointments related to the merger integration.